Establishment Labs to Present at the Cowen 42nd Annual Health Care Conference

Rhea-AI Summary

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a leader in women's health technology, announced that CEO Juan José Chacón-Quirós and CFO Raj Denhoy will present at the Cowen 42nd Annual Health Care Conference on March 7, 2022, at 2:10 PM Eastern Time. A live webcast of the presentation can be accessed on the Establishment Labs investor relations website, with an archived version available afterward. The company specializes in breast aesthetics, offering Motiva Implants® and related products that have been delivered to over 80 countries.

SANTA BARBARA, Calif.--(BUSINESS WIRE)-- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced that Juan José Chacón-Quirós, Founder and Chief Executive Officer, and Raj Denhoy, Chief Financial Officer, will present virtually at the Cowen 42^nd Annual Health Care Conference on Monday, March 7, 2022 at 2:10 pm Eastern Time.

A live webcast of the presentation will be available on the Establishment Labs investor relations website at https://investors.establishmentlabs.com/. An archived version of the webcast will be available on the same website following completion of the event.

About Establishment Labs

Establishment Labs Holdings Inc. is a global medical technology company dedicated to improving women’s health and wellness. The company’s initial focus is breast health, principally breast aesthetics and reconstruction. Establishment Labs offers a portfolio of advanced silicone gel-filled breast implants, branded as Motiva Implants® that include a number of innovative and patented features designed to deliver improved aesthetic and clinical outcomes. Since commercial launch in 2010, approximately 2.0 million Motiva Implants® have been delivered to plastic surgeons in over 80 countries. The company also offers or has under development a number of related products and technologies, including the Motiva Flora® tissue expander and Motiva MIA®, the company’s minimally invasive breast enhancement procedure. In 2018, Establishment Labs received an investigational device exemption (IDE) from the FDA for the Motiva Implant® and began a clinical trial to support regulatory approval in the United States. Motiva Implants® are manufactured at the company’s two facilities in Costa Rica, which are compliant with all applicable regulatory standards under ISO13485:2016 and FDA 21 CFR 820 under the MDSAP program. Please visit our website for additional information at www.establishmentlabs.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220302005281/en/

Investor/Media Contact:

Raj Denhoy

415-828-1044

rdenhoy@establishmentlabs.com

Source: Establishment Labs Holdings Inc.

FAQ

When will Establishment Labs present at the Cowen 42nd Annual Health Care Conference?

Establishment Labs will present on March 7, 2022, at 2:10 PM Eastern Time.

Who will represent Establishment Labs at the Cowen Conference?

Juan José Chacón-Quirós, CEO, and Raj Denhoy, CFO, will represent Establishment Labs.

Where can I watch the Establishment Labs presentation?

The presentation will be available via live webcast on the Establishment Labs investor relations website.

What products does Establishment Labs specialize in?

Establishment Labs specializes in breast aesthetics, including its Motiva Implants®.

How many Motiva Implants® have been delivered globally?

Approximately 2.0 million Motiva Implants® have been delivered to plastic surgeons in over 80 countries.